title: Hepatic resection assisted by ablative therapy for advanced hepatocellular carcinoma.
abstract: OBJECTIVE
  We attempted combinations of resection and ablative therapies (ethanol injection (EI) or radiofrequency therapy (RFA)) in hepatocellular carcinoma (HCC) patients.
  
  
  METHODS
  Thirty-one patients with naive HCC treated from January 2000 to June 2010 were enrolled. All were tumor node metastasis stage III and the number of tumors was countable (< or = 5). Twelve were treated with resection assisted with an ablative therapy (combination group) and 19 with resection only (resection group). Clinical backgrounds and prognosis were investigated.
  
  
  RESULTS
  The total scores for up-to-seven criteria were larger in the combination group than in the resection group (p=0.01), while other clinical background findings were not significantly different between the groups. In the combination group, 10 cases underwent resection combined with RFA and 2 with EI. The 1- and 3-year survival rates were not significantly different between the groups (combination group, 88.2% and 88.2%, respectively; resection group, 90.9% and 80.8%, respectively). There were no severe complications.
  
  
  CONCLUSIONS
  Our results indicate that combination therapy is a therapeutic option for cases with countable HCCs who are difficult to treat by resection only.
authors.affiliation: Center of Gastroenterology, Ehime Prefectural Central Hospital, Ehime, Japan. hirage@m.ehime-u.ac.jp
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hiraoka
authors.forename: Nayu
authors.initials: N
authors.lastname: Tazuya
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hidaka
authors.forename: Takahide
authors.initials: T
authors.lastname: Uehara
authors.forename: Misa
authors.initials: M
authors.lastname: Ichiryu
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nakahara
authors.forename: Atsushi
authors.initials: A
authors.lastname: Tanabe
authors.forename: Yukou
authors.initials: Y
authors.lastname: Shimizu
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Tanihira
authors.forename: Aki
authors.initials: A
authors.lastname: Hasebe
authors.forename: Yasunao
authors.initials: Y
authors.lastname: Miyamoto
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Ninomiya
authors.forename: Hideki
authors.initials: H
authors.lastname: Kawasaki
authors.forename: Hironori
authors.initials: H
authors.lastname: Ochi
authors.forename: Yohei
authors.initials: Y
authors.lastname: Koizumi
authors.forename: Masashi
authors.initials: M
authors.lastname: Hirooka
authors.forename: Masanori
authors.initials: M
authors.lastname: Abe
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Hiasa
authors.forename: Bunzo
authors.initials: B
authors.lastname: Matsuura
authors.forename: Morikazu
authors.initials: M
authors.lastname: Onji
authors.forename: Kojiro
authors.initials: K
authors.lastname: Michitaka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D003131:Combined Modality Therapy; D000431:Ethanol / Q000008:administration & dosage; D005260:Female; D006498:Hepatectomy / Q000379:methods*; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
chemical_list: D000431:Ethanol